Aktis Oncology, Inc. (AKTS) Deep Dive Video

Aktis Oncology offers a high-risk, high-upside radiopharmaceutical platform story: strong cash runway, Lilly validation, promising early dosimetry, and major solid-tumor ambitions balanced against clinical, isotope-supply, and dilution risks.